Insulin glargine-yfgn - Biologic Drug Details

Summary for insulin glargine-yfgn

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for insulin glargine-yfgn

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin glargine-yfgn Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin glargine-yfgn Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for insulin glargine-yfgn Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Insulin Glargine-yfgn

Last updated: February 26, 2026

What is Insulin Glargine-yfgn?

Insulin glargine-yfgn is a biosimilar of insulin glargine, a long-acting insulin used in diabetes management. It was approved by the U.S. Food and Drug Administration (FDA) in December 2022 under the brand name Rezvogl. The drug is a biosimilar product designed to offer a lower-cost alternative to branded insulin glargine products such as Lantus (Sanofi) and Basaglar (Eli Lilly).

Market Landscape

Product Portfolio and Patent Landscape

• Key Brands: Lantus (Sanofi), Basaglar (Eli Lilly), Toujeo (Sanofi)
• Patent Expiry: The primary patents covering Lantus expired in 2015-2017, enabling biosimilar competition.
• Biosimilar Entry: Insulin glargine-yfgn (Rezvogl) entered the U.S. market in 2022 following biosimilar approval.

Market Size and Growth

• Global Insulin Market (2022): Estimated at USD 58 billion, growing at a CAGR of 8.8% (Grand View Research, 2022).
• U.S. Diabetes Market: Approximately USD 44 billion annually, with insulins constituting nearly 40% of the total.
• Biosimilar Penetration: Expected to reach 15-20% of the insulin market within five years post-launch (IQVIA, 2022).

Competitive Position

• Insulin Glargine Biosimilars: Multiple global biosimilars exist, including Sanofi's Lyumjev (faster-acting insulin), which are not direct competitors but influence the market space.
• Pricing Strategy: Biosimilars typically reduce prices by 20-30% relative to brand leaders.

Market Dynamics

Pricing and Reimbursement

• Pricing: The wholesale acquisition cost (WAC) for biosimilar insulin glargine products generally ranges from USD 70 to USD 150 per 10 mL pen, compared to USD 280 for Lantus.
• Reimbursement Policies: Insurers and pharmacy benefit managers (PBMs) favor biosimilars to reduce costs, incentivizing substitution at pharmacy level.
• Patient Access: Reduced copayments and increased formulary coverage contribute to rapid adoption.

Regulatory Environment

• FDA approval of biosimilars mandates demonstration of biosimilarity without clinical efficacy trials.
• Patent litigation and exclusivity periods influence biosimilar market entry timelines.
• International markets differ: the European Medicines Agency (EMA) approved biosimilars earlier, influencing U.S. market dynamics.

Prescriber Acceptance

• Physicians increasingly prescribe biosimilars due to cost savings and regulatory confidence.
• Education campaigns address concerns about efficacy and safety, accelerating adoption.

Manufacturing and Supply Chain

• Biosimilar production requires complex biotechnological processes.
• Supply chain disruptions can impact availability, affecting market penetration.

Financial Trajectory

Revenue Projections

• Initial Launch: Estimated first-year sales range from USD 200 million to USD 500 million (Bloomberg NEF estimates, 2023).
• Five-Year Outlook: With growing market share, revenues could reach USD 2-3 billion by 2027.
• Pricing Trends: Prices are expected to decline further as competition intensifies and manufacturing efficiencies improve.

Key Market Players and Their Strategies

• Eli Lilly: Marketed Basaglar, actively promoting biosimilar adoption through rebates and differentiated delivery options.
• Sanofi: Focuses on maintaining market share with innovative delivery devices like SoloStar.
• Emerging Biosimilars: Companies such as Biocon and Samsung Bioepis aim for international expansion, affecting the US market share.

Investment and R&D Focus

• Companies investing heavily in biosimilar pipelines, aiming to expand insulin and other biologic portfolios.
• R&D expenditures are driven by regulatory compliance, manufacturing complexity, and differentiation strategies.

Challenges and Opportunities

Challenges

• Patent litigation prolongs market entry for some biosimilars.
• Prescriber and patient hesitancy persists, requiring educational initiatives.
• Pricing pressure from payers could impact profit margins.

Opportunities

• Expansion into international markets where biosimilars face fewer regulatory hurdles.
• Developing new delivery systems, such as inhalable or patch-based insulins.
• Formulary inclusion by large insurers amplifies market access.

Key Takeaways

• Insulin glargine-yfgn entered a mature market with significant cost-saving potential.
• The global insulin market is expanding at high double-digit growth rates.
• Biosimilar adoption depends on price competition, regulatory clarity, and prescriber confidence.
• Revenue projections suggest strong growth, potentially reaching USD 2-3 billion within five years.
• Competitive strategies focus on price, supply chain stability, and innovative delivery mechanisms.

FAQs

1. When did insulin glargine-yfgn (Rezvogl) receive FDA approval?
   December 2022.

2. What is the primary advantage of biosimilar insulin glargine-yfgn?
   Its lower price, offering cost savings to payers and patients.

3. What percentage of the insulin market could biosimilars capture within five years?
   Approximately 15-20%.

4. How does patent status influence biosimilar market entry?
   Patent expirations in 2015-2017 enabled biosimilar entry; ongoing litigation and exclusivity periods can delay new competitors.

5. What are the main challenges in biosimilar insulin adoption?
   Regulatory hurdles, prescriber acceptance, and price competition.

---

References

[1] Grand View Research. (2022). Insulin Market Size, Share & Trends Analysis Report.
[2] IQVIA. (2022). Biologic & Biosimilar Market Outlook.
[3] FDA. (2022). Biosimilar Approval Database.